Articles tagged with Type 1 Diabetes
A six-year study found a correlation between vitamin D3 serum levels and subsequent incidence of Type 1 diabetes, suggesting a preventive role for vitamin D3 in this disease. Researchers estimate that achieving an optimal serum level of 25(OH)D at 50 ng/ml can lower the risk of developing type 1 diabetes by half.
Scientists have identified stem cells in the adult pancreas that can be turned into insulin-producing cells, offering a potential cure for type 1 diabetes. This breakthrough discovery provides further evidence of the existence of stem cells beyond embryos and may lead to new treatments for the condition.
Researchers from Benaroya Research Institute, Seattle Children's Research Institute, and University of Virginia are joining forces to study the genetic causes of Type 1 diabetes. The study aims to identify immunologic pathways involved in the disease, which can be targeted for diagnosis and therapy.
Researchers at Thomas Jefferson University found that normalizing the population of protective T regulatory cells in the pancreatic lymph nodes can regenerate insulin-producing beta cells and normalize blood sugar levels in diabetic mice. The study suggests a new approach to confront local autoimmune reactions in type 1 diabetes.
A Scottish study found people with type 1 diabetes have a higher risk of heart attacks, strokes, and premature death compared to the general population. The researchers also discovered that women are more at risk than men, with higher rates of cardiovascular events and deaths from any cause.
A new study suggests that oral insulin may prevent or delay the onset of type 1 diabetes among individuals with autoantibodies against insulin. The study found that participants who took oral insulin had a delayed development of type 1 diabetes compared to those who took placebo capsules. The delaying effect was attributed to the immun...
Researchers aim to develop a biologic cure for diabetes by addressing immunosuppression, poor islet viability, and implantation issues. The new funding will support the development of bioactive scaffolds and conformal coatings to protect implanted cells from the immune response.
A phase I clinical trial confirms that a generic vaccine can kill autoimmune cells targeting insulin-secreting cells, temporarily restoring insulin production in patients with type 1 diabetes. The treatment pathway has been validated in humans and shows early evidence of effectiveness.
The American College of Physicians developed a free curriculum to train internal medicine residents in identifying and eliminating wasteful treatment options. The high-value, cost-conscious care curriculum focuses on patient cases requiring careful analysis of benefits, harms, costs, and evidence-based decision making.
Researchers found that continuous glucose monitoring devices and insulin pumps improve blood sugar levels and reduce time spent with high levels in patients with type 1 diabetes. These new technologies offer a more convenient alternative to traditional methods, but adherence is key to effectiveness.
Researchers at UNC School of Medicine used injections of non-depleting antibodies to rapidly reverse the onset of Type I diabetes in mice. The treatment maintained disease remission indefinitely without harming the immune system, with some animals remaining free of diabetes after over 400 days.
A new study found that adding liraglutide to insulin therapy improves blood sugar control in obese adults with poorly controlled Type 1 diabetes. Patients also experienced significant weight loss and lower blood pressure.
Scientists at Joslin Diabetes Center have identified a new cause of cardiac damage after heart attacks in people with type 1 diabetes. A runaway autoimmune response triggered by alpha-myosin leads to chronic inflammation, cardiomyopathy, and heart failure. The study offers promising targets for future interventions to protect the heart.
A study by Joslin Diabetes Center found that a significant number of people with long-term type 1 diabetes developed little to no diabetic eye disease over time. The researchers hope to identify the factors behind this protection, which could lead to new treatments or prevention strategies.
The Hypoglycemia-Hyperglycemia Minimizer (HHM) System successfully detects blood glucose highs and lows, automatically adjusting insulin delivery to safely manage type 1 diabetes. The study's findings lay the groundwork for further clinical trials and a potential game-changer for millions living with the condition.
Scientists at the Toronto General Hospital Research Institute showed that an experimental bariatric surgery can lower blood sugar levels in non-obese rats with type 1 diabetes. The study demonstrated that duodenal-jejunal bypass surgery activates novel nutrient-sensing signals in the jejunum, rapidly lowering blood sugar levels.
A clinical study demonstrates the effectiveness of an automated insulin dosage titration system in improving blood glucose control and reducing hypoglycemic events. The system, developed by Hygieia, Inc., automatically updates insulin dosage for patients with type 2 or type 1 diabetes, leading to improved glycemic targets.
Researchers have identified significant differences in how diabetes affects Asian populations, including unique markers for type 1 diabetes diagnosis. The study highlights the need for culturally sensitive care, tailored treatment guidelines, and expanded education programs.
The iDEAL study is a Phase II clinical trial evaluating the safety and efficacy of iCo-007 in treating diabetic macular edema. The trial aims to improve visual acuity in patients with DME, a leading cause of blindness in working Americans.
Scientists discover that cellular stress takes place in pancreatic beta cells before T1D onset, potentially igniting autoimmune attack. ER stress response may contribute to beta cell dysfunction and death, shedding light on disease progression and potential therapeutic targets.
Researchers have developed a personalized immune mouse that can recreate an individual's immune system, allowing for unprecedented analysis of abnormalities contributing to type 1 diabetes and other autoimmune diseases. This model has the potential to develop individualized immunotherapies against cancer and infection.
A new JDRF-funded study identifies genes expressed in beta cells, suggesting a role in their own destruction leading to T1D. The research may help explain why the immune system specifically attacks beta cells, opening up new avenues for understanding and treating the disease.
A study from Massachusetts General Hospital found that C-peptide production persists for decades after Type 1 diabetes onset, and beta cell functioning remains intact at low levels. The novel ultrasensitive assay detected C-peptide in 34 of 54 blood samples, suggesting a longer window for therapeutic intervention.
Scientists studied children with newly diagnosed type 1 diabetes to understand its initial stages. They found variability in T-regulatory cell activity and increased immune-boosting cells, which may help develop new treatments.
A study found that automatic suspension of insulin delivery via insulin pumps reduces the severity and duration of hypoglycemia in individuals with type 1 diabetes. The 'low glucose suspend' feature significantly decreases hypoglycemic episodes, reducing the risk of rebound hyperglycemia.
A recent study suggests that seasonal variations in the immune system may impact the effectiveness of a vaccine targeting type 1 diabetes. The vaccine, which uses the GAD65 antigen, showed promise in earlier trials but failed to demonstrate significant effects in its latest phase 3 trial. The study's authors propose that factors such a...
Scientists at Joslin Diabetes Center identified two novel markers that can predict renal failure in patients with Type 1 and Type 2 diabetes, ten years in advance. High concentrations of TNFR1 and TNFR2 accurately predict the risk of renal function loss.
Researchers at Cardiff University have discovered a link between killer T-cells and the development of Type 1 diabetes. The study found that killer T-cells can attack and destroy insulin-producing cells in the pancreas, leading to a lack of insulin and high blood sugar.
Researchers at La Jolla Institute identified specific T cells that trigger type 1 diabetes in humans for the first time in human tissues. The study provides a crucial step in interrupting the disease process and highlights CD8 T cells as key players.
Researchers have discovered a protein called Islet Homeostasis Protein (IHoP) that regulates blood sugar levels by balancing insulin and glucagon. The protein's presence helps maintain healthy glucose levels, while its absence leads to increased glucagon and insulin resistance.
The REMOVAL study aims to test whether metformin can prevent or reduce the risk of cardiovascular complications in people with type 1 diabetes. The five-year trial will follow 500 patients and examine the effects of metformin on blood glucose control, treatment satisfaction, and other complications.
Researchers at Joslin Diabetes Center have identified a critical diagnostic marker that differentiates type 1 from type 2 diabetes in young Asian Americans, highlighting the importance of insulin resistance. The study also found physical differences in Asian patients with diabetes that should inform treatment recommendations.
Researchers at La Jolla Institute create cellular movies showing the destruction underlying type 1 diabetes in real-time, providing new insights into disease process and potential therapeutic directions. The studies use two-photon microscope to illuminate cell processes previously extrapolated from photos or lab experiments.
Researchers found that intensive diabetes therapy can preserve kidney function in patients with type 1 diabetes, preventing impaired kidney function and kidney failure. The study's results demonstrate the importance of maintaining good glucose control early in the course of type 1 diabetes to prevent long-term kidney complications.
A long-term study found that early, intensive glucose-lowering therapy in type 1 diabetes patients prevented impaired glomerular filtration rates and reduced the risk of end-stage kidney disease. Participants who received intensive therapy showed a 50% lower risk of developing impaired GFR over a median follow-up period of 22 years.
Researchers found that connexin 36 protects mouse pancreatic beta-cells against apoptosis triggered by immune molecules prevalent at the onset of Type 1 diabetes. Promoting connexin 36 expression and function could provide a therapeutic strategy to protect beta-cells from immune system attack.
A $3.9 million grant will enable research to identify protective factors that prevent diabetes complications in long-term insulin-dependent diabetes patients. The study aims to find biomarkers and therapeutic agents to halt diabetic retinopathy and nephropathy, which significantly impact lifespan and quality of life.
Researchers discover a compound that prevents Type 1 diabetes in mice and has similar effects on human cells from diabetic patients. The finding signals a new direction in fighting the disease and other autoimmune disorders.
A group of international diabetes researchers have been awarded $4.5 million to engineer an artificial pancreas system that can monitor and adapt to the body's complex physiological changes. The system aims to improve quality of life for patients with type 1 diabetes by treating the condition in their natural environment.
Researchers have identified a non-classical form of fetal immune thrombocytopenia that can lead to miscarriage and habitual abortion. The condition is characterized by excessive platelet activation and blood clot formation in the placenta. New treatments targeting this condition have been suggested, offering hope for women affected by it.
The University of California San Diego is awarded a $5.9 million grant to study kidney complications related to type 1 and type 2 diabetes. The researchers aim to challenge current dogma by examining the link between mitochondrial function, metabolic alterations, and kidney disease.
A large-scale genetic study has uncovered new genes associated with type 1 diabetes, a condition affecting 200 million people worldwide. The research adds to knowledge of gene networks involved in the origin of this complex disorder.
Hebrew University researchers have identified a key signal that prompts production of insulin-producing beta cells, which may help restore or increase beta cell function in people with type 1 diabetes. The study found that glucose levels trigger the regeneration of beta cells through a specific enzyme, glucokinase.
A study by Dr Jay S Skyler and colleagues found that abatacept slows the loss of insulin-producing beta-cells in type 1 diabetes patients, but only for the first six months. The treatment helps modulate T-cell activation, resulting in higher C-peptide levels.
Researchers at St. Michael's Hospital discovered that GABA injections prevented and reversed Type 1 diabetes in mice by regenerating insulin-producing cells and decreasing the immune system's attack on them. This breakthrough finding offers new avenues for prevention and treatment of Type 1 diabetes.
A vaccine targeting glutamic acid decarboxylase (GAD) failed to preserve insulin production in patients with newly diagnosed type 1 diabetes. Researchers suggest that the vaccine may be beneficial for preventing or delaying the onset of the disease, but should not be used in clinical practice.
Researchers found that a strawberry a day may keep doctors away, including neurologists, endocrinologists, and oncologists. Fisetin, a flavonoid compound, reduced complications of diabetes, anxiety-related behaviors, and high blood sugar levels in mice.
Researchers have found that low doses of BCG can temporarily reverse type 1 diabetes in human patients by eliminating autoreactive T cells. A Phase II trial is now underway to test the effectiveness of this approach.
A new study found that people diagnosed with type 1 diabetes can expect to live up to 15 years longer than previously thought. The study, published in the American Diabetes Association's 71st Scientific Sessions, analyzed data from a 30-year prospective study and found a significant improvement in life expectancy among participants.
Mayo Clinic researchers are developing an artificial pancreas that will deliver insulin automatically and with individualized precision, reducing the need for daily insulin dosing and finger pricks. The system includes a blood sugar monitor, automatic insulin pump, activity monitors, and a central processing unit.
Research finds that adolescents and young adults with type 1 diabetes have increased risk of heart attack and stroke due to atherosclerosis in the carotid arteries. The study aims to improve glycemic control and reduce cardiovascular risk factors to prevent cardiovascular disease.
The DIAPREV-IT study, a three-year project funded by the Juvenile Diabetes Research Foundation, aims to vaccinate healthy children at high risk of developing type 1 diabetes. The researchers believe that vaccinating earlier in the disease process can save more beta cells and increase the vaccine's effectiveness.
Researchers at Rensselaer Polytechnic Institute have created a closed-loop artificial pancreas that can automatically monitor blood sugar levels and administer insulin to individuals with Type 1 diabetes. The device aims to reduce the guesswork involved in daily insulin management, which is crucial for maintaining stable glucose levels.
Georgia Health Sciences University researchers are exploring whether low levels of interleukin-1 receptor antagonist (IL-1ra) can identify children at risk for developing type 1 diabetes. They also plan to investigate using IL-1 inhibitors to prevent the disease.
Despite significant advances in kidney care, type 1 diabetes patients with kidney dysfunction continue to face increased risks of kidney failure and heart-related death. New therapies are needed to retard progression to end-stage renal disease.
Researchers analyzed data from 592 patients with type 1 diabetes and macroalbuminuria to identify predictors of End-Stage Renal Disease (ESRD) and pre-ESRD mortality. The study found that poor glycemic control increases ESRD risk but not pre-ESRD mortality, while improved lipid management affects both outcomes.
Researchers at the Medical College of Wisconsin found that children with type 1 diabetes often develop early cardiovascular disease before puberty, characterized by stiffer blood vessels and vascular inflammation. The study highlights the need for long-term studies to monitor the progression of these changes in young patients.
The European Diabetes Research Network, funded by the EU, will investigate the possible role of virus infection in causing type 1 diabetes. The network aims to develop a vaccine to prevent diabetes in children and improve diagnosis and patient care.
UT Southwestern researchers found that eliminating glucagon action can restore glucose tolerance to normal in mice with type 1 diabetes. This suggests a potential 'cure' for the disease, as insulin would no longer be necessary.
A La Jolla Institute team has validated a computer model's ability to predict key information on nasal insulin treatment regimens in type 1 diabetes. The platform accurately predicted biomarker onset and therapeutic outcome, confirming its potential as a valuable research tool.